Molecular Therapy: Nucleic Acids (Mar 2022)

DdCBE mediates efficient and inheritable modifications in mouse mitochondrial genome

  • Jiayin Guo,
  • Xiaoxu Chen,
  • Zhiwei Liu,
  • Haifeng Sun,
  • Yu Zhou,
  • Yichen Dai,
  • Yu'e Ma,
  • Lei He,
  • Xuezhen Qian,
  • Jianying Wang,
  • Jie Zhang,
  • Yichen Zhu,
  • Jun Zhang,
  • Bin Shen,
  • Fei Zhou

Journal volume & issue
Vol. 27
pp. 73 – 80

Abstract

Read online

Critical mutations of mitochondrial DNA (mtDNA) generally lead to maternally inheritable diseases that affect multiple organs and systems; however, it was difficult to alter mtDNA in mammalian cells to intervene in or cure mitochondrial disorders. Recently, the discovery of DddA-derived cytosine base editor (DdCBE) enabled the precise manipulation of mtDNA. To test its feasibility for in vivo use, we selected several sites in mouse mtDNA as DdCBE targets to resemble the human pathogenic mtDNA G-to-A mutations. The efficiency of DdCBE-mediated mtDNA editing was first screened in mouse Neuro-2A cells and DdCBE pairs with the best performance were chosen for in vivo targeting. Microinjection of the mRNAs of DdCBE halves in the mouse zygotes or 2-cell embryo successfully generated edited founder mice with a base conversion rate ranging from 2.48% to 28.51%. When backcrossed with wild-type male mice, female founders were able to transmit the mutations to their offspring with different mutation loads. Off-target analyses demonstrated a high fidelity for DdCBE-mediated base editing in mouse mtDNA both in vitro and in vivo. Our study demonstrated that the DdCBE is feasible for generation of mtDNA mutation models to facilitate disease study and for potential treatment of mitochondrial disorders.

Keywords